The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.
 
Davide Melisi
Consulting or Advisory Role - Lilly; Shire
Travel, Accommodations, Expenses - Celgene
 
Susan C. Guba
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Travel, Accommodations, Expenses - Lilly
 
Maria Karasarides
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Valerie Andre
Employment - Lilly
Stock and Other Ownership Interests - Lilly